iPSC-derived products present unique risks related to genomic instability, incomplete differentiation, and tumorigenicity. Standard analytical panels are insufficient. A tailored approach is needed to create a comprehensive profile that confirms the identity of the final cell type while simultaneously proving the absence of harmful residual pluripotent cells, a key requirement for ATMP submissions to bodies like the MHRA.

Regulatory authorities expect a robust characterization package using orthogonal methods. For identity, this includes flow cytometry for cell surface markers and gene expression analysis. For purity, this involves highly sensitive assays to detect process-related impurities and requires sensitive detection of undifferentiated stem cells to mitigate tumorigenicity risk. The data must provide a clear link between the manufactured product and its proposed mechanism of action and safety profile.

We develop and qualify or validate all immunogenicity and bioanalytical assays in a phase-appropriate manner, adhering to GxP guidelines. Our process ensures that the methods used to characterize your iPSC-derived product will generate data suitable for inclusion in global regulatory submissions, supporting an 18-24 month timeline to get candidates to IND.

The clinical potential of iPSC-derived therapeutics is matched by their manufacturing and analytical complexity. The final product is a living cell population whose safety and efficacy depend entirely on its precise identity, purity, and functional competence.

A one-size-fits-all testing template does not exist. A data-driven preclinical strategy must be tailored to the specific cell type, target indication, and delivery route. This requires a deep understanding of the potential failure modes, from incomplete differentiation to immunogenic reactions against process residuals.